

CURRICULUM VITAE

A. PERSONAL INFORMATION

Name: John Vincent Brown III, M.D.
Date of Birth: February 11, 1958
Place of Birth: Kansas City, Missouri
Business Address: 351 Hospital Road
Suite 507
Newport Beach, CA 92663
(949) 642-1361
Fax (949) 642-1394

B. EDUCATION

Undergraduate: University of Kansas
B.S., 1980
Major: Organismal Biology
Cumulative GPA 3.93
Graduation with Distinction

Medical School: University of Kansas School of Medicine
M.D., 1984
Position in Graduating Class, 24/144

Postgraduate Training: University of California at Los Angeles
School of Medicine
Division of Gynecologic Oncology
Fellowship: July 1, 1988 to June 30, 1990

University of Washington Medical School
Department of Obstetrics and Gynecology
Residency: July 1, 1984 - June 30, 1988

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

C. MEDICAL LICENSURE

Washington: 025209 (1985)
California: G62749 (1988)

D. CERTIFICATION

Diplomate of the American Board of Obstetrics and Gynecology (1991)

Certificate of Special Qualification in Gynecologic Oncology (1994)

Recertified in Obstetrics and Gynecology and Gynecologic Oncology (1999)

E. PROFESSIONAL BACKGROUND

ACADEMIC APPOINTMENTS

Assistant Clinical Professor
University of California at Los Angeles
School of Medicine
Harbor/UCLA Medical Center
June 25, 1990 – 1999

Assistant Clinical Professor
University of Southern California
School of Medicine
October, 1999—present

PROFESSIONAL EMPLOYMENT

Private Practice specializing in Gynecologic Oncology
Newport Beach, CA
1990-present

F. AWARDS

Summerfield Scholar, 1977

Veta B. Lear Award
(4.0 GPA for Freshman year), 1977

Owl Society (Junior Men's Honorary Society), 1979

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Mortar Board, 1980

Omicron Delta Kappa (Vice President), 1980

Educational Foundation Scholarship, 1980

Phi Kappa Phi, 1980

J. George Moore Award (Best paper by a fellow, Western
Association Gynecologic Oncologists), 1990

G. PROFESSIONAL SOCIETIES

American College of Obstetricians and Gynecologists (Fellow)

Society of Gynecologic Oncologists (Member)

American College of Surgeons (Fellow)

American Society of Clinical Oncologists (Member)

Western Association of Gynecologic Oncologists (Member)

Society of Surgical Oncologists (Member)

International Society of Gynecologic Cancer (Member)

Pacific Coast Obstetrical and Gynecological Society (Member)

H. PUBLICATIONS

Brown JV, Stenchever MA. Cavernous lymphangioma of the vulva.
Obstet Gynecol 1989;73:877-9.

Brown JV, Fu YS, Berek JS. Ovarian metastases are rare in stage I adenocarcinoma of the
cervix. Obstet Gynecol 1990;76:623-6.

Brown JV, Peters WA, Corwin DJ. Invasive carcinoma after cone biopsy for cervical
intraepithelial neoplasia. Gynecol Oncol 1991;40:25-28.

Brown JV, Karlan BY, Greenspoon JS, Rosove MH, Lagasse LD. Perioperative
coagulopathy in patients undergoing primary cytoreduction. Cancer 1993;71:2557-61.

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Malfetano J, Brown J, Abrams J, Homesley H, Benegno B, Braly P, Bean L, Malta E, Dziem G. Filgrastim (r-met-HuG-CSF) as an Adjunct to Cyclophosphamide and Carboplatin Chemotherapy in Advanced Ovarian Carcinoma. *Proc Am Soc Clin Oncol* 1993;12:265.

Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV. Single dose Dexamethasone Taxol premedication. *Gynecol Oncol*; 69:122-124, 1998.

Micha JP, Brown JV. Primary surgical cure of stage III-B cervical carcinoma with adnexal metastasis. *Gynecol Oncol*; 71, 317-319, 1998

Micha JP, Rettenmaier MA, Francis L, Willenberg R, Brown JV. "Medically necessary" panniculectomy to facilitate radical pelvic surgery in morbidly obese patients. *Gynecol Oncol*; 69:237-242, 1998

Brown JV, Rettenmaier MA, Dillman R, Birk C, Culkin K, Micha JP. Three hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer. *Gynecol Oncol*; 68:166-168, 1998

Dillman RO, Nayak SK, Johnson D, Brown J, Chico S. The potential to use short-term cultures of ovarian cancer cells as autologous tumor cell vaccines. *Proc Am Assoc Cancer Res* 1997; 38:399, abstract 2676.

Dillman RO, Nayak SK, Brown JV, Mahdavi K, Beutel LD. The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer. *Cancer Biother* 1999;14:443-49.

Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day Topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. *Gynecol Oncol* 79; 2000.

P Sabbatini, J Brown, Carol Aghajanian, M L Hensley, S Pezzulli, C O'Flaherty, M Lovegren, S Funt, M Warner, P Mitchell, M G Bolton, D Spriggs, B Duggan. A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. *Proc Am Soc Clin Oncol* 2002; abstract 871.

Brown JV, Peters WA, Rettenmaier MA, Dillman RA, Smith MR, Drescher CW, Micha JP. Three Consecutive Day Topotecan is an Active Regimen for Recurrent Epithelial Ovarian Cancer. *Gynecol Oncol* 2003;88:136-140.

Rettenmaier MA, Brown JV, Micha JP. Modified vestibulectomy is inadequate treatment for secondary vulvar vestibulitis. *Int J Gynecol Surg* 2003;19(1):13-18.

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV. Pilot Study of Outpatient Paclitaxel, Carboplatin and Gemcitabine for Advanced Stage Epithelial Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer. *Gynecol Oncol* 2004;94:719-724

Micha JP, Goldstein BH, Hunter JV, Rettenmaier MA, Brown, JV. Long-term survival in an Ovarian Cancer Patient with Brain Metastases: A Case Report. *Gynecol Oncol* 2004;92:978-980.

Brown JV, Goldstein BH, Rettenmaier MA, Aylward MM, Graham CL, Micha JP. Laser ablation of surgical margins after excisional partial vulvectomy for VIN: Effect on recurrence. *J Repro Med* 2005;50:345-350.

Rettenmaier MA, Goldstein BH, Brown JV, John CR, and Micha JP. Impact of Gynecologic Oncologists on Referral Patterns and Care of Patients with Uterine Malignancies at a Community Hospital. *Int J Gynecol Surg* 2004;20: 57-63.

Micha JP, Goldstein BH, Rettenmaier MA, Brown JV. Cecal pelvic transposition following total pelvic exenteration. *Gynecol Oncol* 2004;94:589-592.

Micha JP, Goldstein BH, Robinson PA, Rettenmaier MA, Brown JV. Abdominal/Pelvic Coccidioidomycosis. *Gynecol Oncol* 2005; 96: 256-258.

Micha JP, Goldstein BH, Mattison JA, Bader KM, Graham C, Rettenmaier MA, Brown JV, Markman M. Experience with single agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. *Gynecol Oncol* 2005;96:132-5.

Sabbatini P, Aghajanian C, Dizon D, Anderson S, Duport J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. *J Clin Oncol* 2004; 22: 4523.

Brown JV, Goldstein BH, Duma CM, Rettenmaier MA, Micha JP. Gamma-Knife Radiosurgery for the Treatment of Ovarian Cancer Metastatic to the Brain. *Gynecol Oncol* 2005; 97; 858-61 .

Micha JP, Goldstein BH, Bock BV, Rettenmaier MA, Brown III JV. Spontaneous Bacterial Peritonitis. *Int J Gynecol Cancer* 2006; 16: 908-911.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV, John CR, Markman M. Surgery Alone or Surgery with a Combination Radiation or Chemo-Radiation for Management of Patients with Bulky Stage 1B2 Cervical Carcinoma. *Intl J Gynecol Cancer* 2006; 16: 1-5.

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. A Rare Case of Coccygeal Endometriosis. *Obstet Gynecol* 2006; 107:1-2.

Rettenmaier MA, Goldstein BH, Brown III JV, Van Horn D, Micha JP. Recurrent gestational trophoblastic disease following persistently normal hCG titers: A rare occurrence. Accepted to the *Am J Clin Oncol* 2005.

Rettenmaier MA, Goldstein BH, Stallman JM, Brown III JV, Micha JP. Greatly Elevated Serum CA-125 Level in a Patient with a Ruptured Endometrioma. *J Gynecol Surg* 2005; 21: 109-112.

Rettenmaier MA, Goldstein BH, Epstein HD, Brown JV 3rd, Micha JP. Serous psammocarcinoma of the ovary: An unusual finding. *Gynecol Oncol* 2005; 99:510-11.

Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown III JV. Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions. *Gynecol Oncol* 2006; 100: 437-438.

Brown JV, Goldstein BH, Rettenmaier MA, Michelle MM, Graham CL, Micha JP. Laser Ablation of Surgical Margins After Excisional Partial Vulvectomy for VIN. *Obstet Gynecol Surv* 2005;60:584-5.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV Pelvic Radiation Necrosis and Osteomyelitis Following Treatment for Advanced Cervix Carcinoma. *Gynecol Oncol* 2006; 101: 349-352.

Rettenmaier MA, Goldstein BH, Stallman JM, Brown III JV Micha JP. Lymphoepithelial carcinoma of the cervix: Review and treatment course. *J Gynecol Surg* 2006; 21: 185-88.

Micha JP, Goldstein BH, Rettenmaier MA, Brown JV III, John Markman M. Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma. *Int J Gynecol Cancer* 2006; 16: 1-5.

Micha JP, Goldstein BH, Epstein HD, Rettenmaier MA, Brown III JV. Ovarian Cancer Metastatic to the Breast. *Gynecol Oncol* 102: 386-390.

Rettenmaier MA, Goldstein BH, Stallman JM, Micha JP, Brown III JV. Vaginal reconstruction following supra-levator exenteration. *Gynecol Oncol* 102: 397-399.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. Neo-vagina Reconstruction Utilizing the Bladder and Urethra Following Radical Radiation Therapy. *J Gynecol Surg* 2006;22:73-75.

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Micha JP, Goldstein BH, Zusman D, Rettenmaier MA, Epstein HD Brown III JV. Malignant Pericardial Effusion Secondary to Ovarian Adenocarcinoma. Accepted to J Repro Med 2006.

Rettenmaier MA, Goldstein BH, Haghighi B, Brown III JV, Micha JP. Serous endometrial intraepithelial carcinoma: Diagnosis and clinical management. J Gynecol Surg 2006;22: 69-72.

Micha JP, Goldstein BH, Rettenmaier MA, Brown III JV. A response to Batt in A rare case of precoccygeal endometriosis. Accepted to Obstets and Gynecol 2006. (Response to Letter to Editor).

I. PRESENTATIONS

Brown JV, Karlan BY, Lagasse LD. Improved cytoreduction with the Ultrasonic Surgical Aspirator. Western Association of Gynecologic Oncologists. May, 1989.

Brown JV, Fu YS, Berek JS. Ovarian metastases are rare in stage I adenocarcinoma of the cervix. Western Association of Gynecologic Oncologists. June, 1990.

Brown JV, Karlan BY, Rosove MH, Leuchter R, Futoran R, Lagasse LD. Perioperative coagulopathy in patients undergoing primary cytoreduction. Western Association of Gynecologic Oncologists. June, 1991.

Brown JV, Rettenmaier MA, Micha JP. A pilot study of oral etoposide for recurrent or persistent ovarian cancer. Western Association of Gynecologic Oncologists. June, 1992.

Brown JV, Rettenmaier MA, Micha JP, Tullio R, Burke C. Taxol and Carboplatin is an effective outpatient regimen for advanced ovarian cancer. Western Association of Gynecologic Oncologists. June, 1995.

Dillman RO, Nayak SK, Johnson D, Brown J, and Chico S. The potential to use short-term cultures of ovarian cancer autologous tumor cell vaccines. American Association for Cancer Research. March, 1997.

Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day Topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Society of Gynecologic Oncologists. February, 2000.

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Brown JV, Peters WA, Rettenmaier MA, Dillman RA, Smith MR, Drescher CW, Micha JP. Three Consecutive Day Topotecan is an Active Regimen for Recurrent Epithelial Ovarian Cancer. Society of Gynecologic Oncologists. March, 2002.

P Sabbatini, J Brown, Carol Aghajanian, M L Hensley, S Pezzulli, C O'Flaherty, M Lovegren, S Funt, M Warner, P Mitchell, M G Bolton, D Spriggs, B Duggan. A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. American Society of Clinical Oncologists. May, 2002.

Sabbatini P, Brown J, Bolton M. Phase I/II study of PG-paclitaxel (CT 2103) in patients with recurrent ovarian cancer. European Spring Oncology Conference. June, 2002.

Sabbatini P, Brown J, Peters WA, Andrew J, Mehdi A, Crozier MA, Rivkin S, Bolton MG. Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer. Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecologic Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Stockton Hematology Oncology Medical Group; Southwest Regional Cancer Center; Swedish Medical Center and Tumor Institute; Cell Therapeutics, Inc, Seattle, WA. European Organisation for Research and Treatment of Cancer (EORTC). November, 2002.

Peters WA, Brown JV, Rivkin S, Bolton MG, Sabbatini P. Phase I/II Study of CT-2103 (Xyotax) in Patients with Recurrent Ovarian Cancer. Society of Gynecologic Oncologists. February, 2003.

Brown JV, Goldstein BH, Rettenmaier MA, Aylward MM, Graham CL, Micha JP. Laser ablation of surgical margins following excisional partial vulvectomy for vulvar intraepithelial neoplasia may decrease recurrences. Pacific Coast Obstetrical and Gynecological Society. September, 2003.

Micha, JP, Goldstein BH, Rettenmaier, MA, Mattison J, Graham CL, Birk CL, and Brown JV. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube epithelial cancer. Eli Lilly Investigators Meeting March 2003, Phoenix, AZ.

Micha, JP, Goldstein BH, Rettenmaier, MA, Mattison J, Graham CL, Birk CL, and Brown JV. Paclitaxel, carboplatin and gemcitabine for treatment of advanced stage ovarian cancer. Eli Lilly Investigators Meeting April 2004, Phoenix, AZ.

J. RESEARCH GRANTS.

Bristol Myers Squibb

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Principle Investigator

Phase I/II study of intravenous paclitaxel and carboplatin in patients with stage III/IV epithelial ovarian cancer (Three hour paclitaxel infusion)

Principle Investigator

Phase II study of intravenous paclitaxel and carboplatin in patients with stage III/IV epithelial ovarian cancer (One hour paclitaxel infusion)

Amgen

Co-Principle Investigator

Filgrastim (r-met-HuG-CSF) as an Adjunct to Cyclophosphamide and Carboplatin Chemotherapy in Advanced Ovarian Carcinoma

Smith Kline Beecham

Principle Investigator

A phase I/II trial of topotecan in patients with platinum and taxane refractory epithelial ovarian cancer

Principle Investigator

A phase II trial of three day topotecan q 21 days for recurrent epithelial carcinomas of the ovary, fallopian tube, and peritoneum.

Eli Lilly

Sub - Investigator

Phase II Trial of Intravenous Taxol, Carboplatin, and Gemzar in Patients With Stage III/IV Epithelial Ovarian Cancer, Stage III/IV Fallopian Tube Epithelial Cancer, Stage III/IV Endometrial Adenocarcinoma, Stage III/IV Malignant Primary Peritoneal Mesothelioma, and Stage III/IV Peritoneal Cancer

Eli Lilly

Principle Investigator

A Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced, Persistent, or Recurrent Carcinoma of the Cervix

Ortho Biotech

Principle Investigator

A Phase II Trial of Doxil and Carboplatin for the Treatment of Advanced, Recurrent, or Persistent Endometrial Carcinoma

Cellpath

Sub – Investigator

A Phase II Trial of CP4071 (Digitoxin) In Patients With Recurrent Epithelial Mullerian Adenocarcinoma

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Altarex

Sub – Investigator

A randomized, double-blind, placebo-controlled, phase IIB study of the safety and efficacy of OvaRex (MAb-B43.13) in ovarian cancer patients with an elevated serum CA-125 but without other evidence of disease

Altarex

Sub – Investigator

A multi-center clinical trial of intravenous OvaRex (MAb-B43.13) as post-chemotherapy consolidation for ovarian, tubal and peritoneal carcinoma

Atairgin Technologies, Inc.

Sub – Investigator

A clinical protocol to evaluate the role of lysophosphatidic acid as an aid in the differential diagnosis of ovarian cancer in women scheduled for surgery with a pelvic mass or a suspected ovarian malignancy

Atairgin Technologies, Inc.

Sub – Investigator

A protocol to characterize lysophosphatidic acid assay levels in women not suspected of ovarian cancer

Eli Lilly

Sub – Investigator

A Randomized Phase III Trial of Gemzar versus Doxil with Crossover Treatment Option for Patients with Platinum-Resistant Ovarian, Fallopian Tube, Peritoneal Cancer.

GlaxoSmithKline

Principle Investigator

A Phase II, Multi-Center Trial of Weekly Topotecan in Patients With Recurrent Platinum Sensitive Epithelial Cancers of the Ovary, Fallopian Tube, and Peritoneum

The ANA Study Group

Sub – Investigator

The ANC Study Group Registry: A Prospective Study of Neutropenic Complications

Online Collaborative Oncology Group (OCOG)

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Sub – Investigator

A Randomized, Open-Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients with Non-Myeloid Malignancies Receiving Chemotherapy

Unither

Sub – Investigator

A Double Blind, Placebo-Controlled, Multicenter Clinical Trial Of Intravenous OvaRex Mab-B43.13 As Post-Chemotherapy Consolidation For Epithelial Carcinoma Of Ovarian, Tubal Or Peritoneal Origin

Cell Therapeutics

Site Principal Investigator

A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer

Telik

Sub – Investigator

Phase 3 Randomized Study of TLK286 versus Doxil/Caelyx or Hycamptin as Third-Line Therapy in Platinum Refractory or resistant Ovarian Cancer

Cell Therapeutics

Principle Investigator

CT-2103/Carboplatin for Patients with Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase II Study

K. COMMITTEES/LEADERSHIP

Obstetrics and Gynecology Core Committee, Irvine Medical Center

Society of Gynecologic Oncology Education and Exhibit Ad Hoc Committee:
1997-1999.

Cancer Committee, Hoag Memorial Presbyterian Hospital: 2000-present.

Society of Gynecologic Oncology Clinical Practice Committee: 2001-present.

Co-Director, Society of Gynecologic Oncologists Winter Meeting 1999-present

JOHN VINCENT BROWN, M.D.
CURRICULUM VITAE

Co-Chair of Society of Gynecologic Oncology Clinical Practice Committee: 2004

Chair of Society of Gynecologic Oncology Clinical Practice Committee: 2005-

American College of Surgeons Committee on Applicants: 1998-2003.

Obstetrics and Gynecology Core Committee, Hoag Memorial Presbyterian Hospital:
2003-present.

Council Member of Society of Gynecologic Oncologists; 2005-

Gynecologic Cancer Foundation Nominating Committee, 2006

Revised 07/25/06